Bellerophon Therapeutics (NASDAQ:BLPH) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01, Fidelity Earnings reports.
Shares of BLPH traded down $0.02 during trading hours on Thursday, reaching $0.43. 46,200 shares of the company traded hands, compared to its average volume of 249,757. The stock has a market capitalization of $29.97 million, a P/E ratio of -1.26 and a beta of -0.05. The company has a quick ratio of 2.64, a current ratio of 2.64 and a debt-to-equity ratio of 0.15. Bellerophon Therapeutics has a 12-month low of $0.37 and a 12-month high of $1.22. The business has a fifty day moving average price of $0.48 and a 200-day moving average price of $0.59.
A number of equities research analysts have recently weighed in on BLPH shares. ValuEngine lowered shares of Bellerophon Therapeutics from a “hold” rating to a “sell” rating in a report on Monday. Maxim Group reissued a “buy” rating and set a $2.00 price objective on shares of Bellerophon Therapeutics in a report on Thursday.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.
See Also: Market Timing
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.